Filing Flows › Rani Therapeutics Holdings (RANI) › Q1 2025
Rani Therapeutics Holdings (RANI) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 13, 2025
Rani Therapeutics Holdings (RANI) reported revenue of $172K for the first quarter 2025 (Q1 2025) and -83% from the quarter before.
Rani Therapeutics Holdings, Q1 2025: revenue $172K, net loss $12.7M, operating cash flow −$8.1M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $172K | -83% | — |
| Operating profit | −$12.0M | — | — |
| Net earnings | −$12.7M | — | — |
| Operating cash flow | −$8.1M | — | — |
What changed
Revenue was $172K in Q1 2025, down 83% from the previous quarter.
Operating costs exceeded revenue by $12.0M, an operating margin of -6984.3%. The quarter ended with a net loss of $12.7M, narrower than the previous quarter's $15.7M loss. Minority interests bore $5.5M of it: to shareholders the quarter was a loss of $7.3M.
Operating cash flow was −$8.1M. Non-cash charges added back $251K of depreciation and amortization and $3.9M of share-based compensation. Working capital and other items added $413K. Capital expenditures of $51K exceeded it, leaving free cash flow of −$8.2M.
Questions
What was Rani Therapeutics Holdings' revenue in the first quarter 2025?
Rani Therapeutics Holdings (RANI) reported revenue of $172K for the first quarter 2025 (Q1 2025) and -83% from the quarter before.